Syngene International, India’s largest contract research organization, has slated an expansion of its ongoing research collaboration with Amgen Inc. As a result, the Bengaluru-based CRO will expand the Syngene Amgen Research & Development Center (SARC) in terms of size and scope of its operations.
 
SARC, the 25,000 sq. ft dedicated R&D Center for Amgen, was established in 2016 in Bengaluru. India. It currently has a team of approximately 100 highly qualified Syngene scientists working closely with Amgen researchers around the world on the discovery and development of innovative medicines.
 
With the expansion, the floor space of SARC will double to 50,000 sq. ft. A team of up to 185 multi-disciplinary Syngene scientists will work in the areas of medicinal and process chemistry, biologics, bioprocess development, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development.
 
Commenting on the expansion, Jonathan Hunt, Chief Executive Officer, Syngene International, said, "We are delighted with the expansion of our research collaboration with Amgen. This expansion underscores Syngene’s capabilities to execute complex integrated discovery and development projects for Amgen. We are committed to working closely with Amgen’s global scientific teams and look forward to SARC playing an increasingly important role in supporting their R&D activities that could benefit patients worldwide.”
 
The expansion of SARC will be customized to meet Amgen's functional requirements and will include a range of environment-friendly features that will enable optimal utilization of the laboratory space, he added.